US FDA grants final approval to Zyduss Micafungin for injection
October 26, 2022 :
The United States Food and Drug Administration (FDA) has granted final approal to ZydusLifesciences for marketing Micafungin for injection, 50 mg/vial and 100 mg/vial, single-dose vials, ZydusLifesciences notified in a statement.
According to the statement, Micafungin for injection is indicated to treat variety of fungal infections. It is also used to prevent fungal infections in patients who are having a stem cell transplant. The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara, India.
ExpressPharma